New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2013
14:45 EDTINCYIncyte presents final results from a Phase I trial of INCB024360
Incyte presented final results today from the Phase I clinical trial for its oral indoleamine dioxygenase-1 IDO1, inhibitor, INCB024360, at the American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago. IDO1 inhibition may provide a new approach in enhancing the immune system in patients with a variety of solid tumors. Data demonstrate that INCB024360 achieves greater than 90 percent inhibition of IDO1 at generally well-tolerated doses and may represent a new treatment option for advanced malignancies. Data suggest the potential for INCB024360 to be used as monotherapy or in combination with other cancer agents
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
18:41 EDTINCYIncyte upgraded to Neutral from Sell at Goldman
Subscribe for More Information
13:35 EDTINCYIncyte price target raised to $80 from $69 at Piper Jaffray
Piper Jaffray raised its price target for Incyte shares to $80 saying Jakafi demand was strong in Q3. Piper keeps an Overweight rating on the stock.
07:11 EDTINCYIncyte reports Q3 EPS 33c, may not compare to consensus 0c
Reports Q3 revenue $198.15M, consensus $149.92M. The Company now expects that 2014 net product revenues from Jakafi will be in the range of $350 million to $360 million, an increase from the previous range of $330 million to $340 million.
October 21, 2014
07:54 EDTINCYLeerink a buyer of Alkermes, ImmunoGen, Incyte
Subscribe for More Information
October 17, 2014
08:01 EDTINCYIncyte names Gryska CFO to succeed Hastings
Incyte announced the appointment of David Gryska as Executive Vice President and CFO, effective October 31. Gryska will succeed David Hastings, who has served as Incyte’s Executive Vice President and CFO since October 2003. Hastings, who is leaving the company to pursue other opportunities, will remain with Incyte through the end of November and will work closely with Gryska to ensure a seamless transition.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use